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I. INTRODUCTION 
If you have ever filled a drug prescription at any pharmacy in the 
United States, you have heard the words, “so, would you like brand 
name or generic?”  Originator drugs (brand name drugs), those 
chemically-synthesized and biotechnology derived are the original 
drugs constructed in laboratories.1  These drugs are put through 
various clinical tests,2 and the originator company relies on various 
forms of intellectual property rights and patents in order to justify the 
initial investment required to bring the drug to market in the U.S.3  
Typically, originator patents last for several years, thus guaranteeing 
that the originator company will be the only legal distributor of the 
drug.  Almost all originator drugs are more expensive than their 
generic counterparts.4  Generic drugs are “duplicative copies of 
                                                 
* Michael Vincent Ruocco is a second year student at Pepperdine University 
School of Law.  Michael graduated from the University of San Francisco with a 
Bachelor of Arts in Politics.  He would like to thank Alex Baumann for her help 
and guidance during the writing process.  He would also like to thank his girlfriend 
Emily Rose Casey for her loving support. 
 
1 The Pharmaceutical Industry in the United States, SELECT USA, 
http://selectusa.commerce.gov/industry-snapshots/pharmaceutical-industry-united-
states (last visited May 21, 2013) [hereinafter “Select USA: Pharm Industry”]. 
2 Id.  Originator drugs are tested first on animals, and then humans, in what are 
referred to as clinical tests.  Id. 
3 Id.  The major obstacle facing drug manufacturers, consumers, and insurance 
companies nationwide is the cost associated with bringing a pharmaceutical drug to 
market in the United States.  Pharmaceutical Research and Manufacturers of 
America (PhRMA) “represents the country’s leading pharmaceutical research and 
biotechnology companies, which are devoted to inventing medicines that allow 
patients to live longer, healthier, and more productive lives.”  About PhRMA, 
PHRMA, http://www.phrma.org/about/about-phrma (last visited Mar. 8, 2013).  
According to PhRMA, “the average cost to develop one new approved drug–
including the cost of failures–[is $1,200,000,000.]”  Chart Pack: 
Biopharmaceuticals in Perspective, PHRMA (2012), available at 
http://www.phrma.org/sites/default/files/pdf/phrma_chart_pack.pdf.  
4 Select USA: Pharm Industry, supra note 1.  For example, filling my 
prescription for Adderall is a perfect example of how prices can drastically vary 
between brand name and generic brand versions of a drug.  Adderall is the brand 
name version of a psychostimulant medication that is used to help treat attention 
deficit hyperactivity disorder (ADHD).  The medication contains a combination of 
four different amphetamine salts: racemic amphetamine aspartate monohydrate, 
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chemically-synthesized drugs that contain the same active ingredient, 
are identical in strength, dosage, form and route of administration,” 
and can only be marketed once the originator’s patent expires.5  
Generic drugs are attractive to most consumers because they are 
typically sold at substantially lower prices than the originator drugs.6  
For a middle class family paying for things such as tuition, gas bills, 
grocery bills, and various other expenses, it is helpful in managing 
the family’s budget to have the choice of purchasing generic drugs 
that have the exact same ingredients and chemical effects as the 
brand name version. 
Many families are unable to purchase generic versions of certain 
brand name drugs because the brand name manufacturers prevent 
generic versions of the drug from coming to market.  They do this for 
one reason, and one reason only: PROFIT.7  The United States of 
                                                 
racemic amphetamine sulfate, dextroamphetamine saccharide, and 
dextroamphetamine sulfate.  When I go to Rite Aid to fill my prescription for thirty 
capsules of Adderall, I have the choice between the brand name (Adderall) and its 
generic form.  Adderall (brand name) comes in a time-release form (a technology 
used in drug capsules that helps dissolve the prescription drug into the blood stream 
over a certain period of time), while the generic form of Adderall comes in an 
“instant release” (instant release means the capsule or tablet is released into the 
blood stream immediately).  On the one hand, if I elect to have my prescription for 
thirty capsules filled with brand name Adderall without first meeting my $5,000 
deductible with Anthem Blue Cross, the total cost to fill my prescription is $125.  
Yet, if the pharmacist fills the prescription with the generic form of Adderall, and I 
have not yet met my deductible, the total cost is only $15.  Therefore, I always 
choose the generic brand.  
5 Select USA: Pharm Industry, supra note 1.  The “route of administration” 
typically refers to whether a drug is administered with time release or instant 
release technology.  See supra note 4. 
6 Many consumers have some type of health insurance that requires them to 
pay a certain amount of money for their doctor visits, prescriptions, etc. before the 
insurance company will help cover their medical costs.  It is much more cost 
effective for the average consumer to purchase the generic form of a drug, as 
typically the generic version is much less expensive than the brand name version, 
especially if the insurance is not helping them pay for it.  See supra note 4.  
7 Take for example the drug Viagra, which is manufactured by Pfizer and is a 
brand name drug used to treat erectile dysfunction in men.  Viagra was approved 
by the FDA in 1998 and sales of the drug surpassed 1,000,000,000 its first year.  
See David L. Shedlarz, Pfizer Inc. Financial Report (1998).  According to Phrma, it 
should have cost Pfizer $1,200,000,000 to bring the drug to market in the U.S.  See 
supra note 3 explaining how much it costs to introduce a pharmaceutical drug in 
the U.S.  Pfizer made almost all of the money that it cost them to research and 
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America is currently home to the world’s largest market for 
pharmaceuticals and is the forerunner in biopharmaceutical research.8  
It is estimated that U.S. pharmaceutical companies conduct eighty 
percent of the world’s research on biopharmaceutical drugs and own 
most of the intellectual property rights to the new drugs that are 
developed.9  “Americans . . . spend a staggering $200 billion a year 
on prescription drugs, and that figure is growing at a rate of about 12 
percent [per] year (down from a high of 18 percent in 1999).”10  The 
U.S. pharmaceutical market has a favorable patent and regulatory 
environment, which allows pharmaceutical companies to freely price 
their drugs at whatever price level the market can sustain.11  The 
success of a drug is largely based on its safety, quality, and 
efficacy.12  Drug manufacturers are constantly competing with one 
another to produce the best product possible.  Due to the free range of 
research, pricing, and marketing, the U.S. market is the preferred 
industry for major pharmaceutical companies.  
This case note delves into the United States Supreme Court’s 
recent decision in Caraco Pharmaceutical Laboratories, Ltd. v. Novo 
                                                 
develop the drug back within one year of the drug’s approval.  Viagra continued to 
do well, and in 2006 the drug made $1,600,000,000 in sales, representing 3.4% of 
Pfizer's total revenue of $48,000,000,000 for 2006.  See Alan Levin, Pfizer Inc. 
Financial Report (2006).  The drug continues to do well and in 2011, the drug made 
$1,981,000,000 in revenue.  See Frank D’Amelio, Pfizer Inc. Financial Report 
(2011). 
8 Select USA: Pharm Industry, supra note 1.  The U.S. is home to the largest 
and most innovative biopharmaceutical research in the entire world.  
Biopharmaceutical Research Sector is Global Leader in Innovation, PHRMA, 
http://www.phrma.org/about/biopharmaceuticals (last visited Jan. 25, 2013).  The 
FDA has approved more than three hundred million drugs in the past decade.  Id.  
Biopharmaceutical research has led to some of the most groundbreaking 
discoveries in medicine, such as HIV medication, which has transformed the virus 
from a death sentence into a manageable condition.  Id. 
9 Select USA: Pharm Industry, supra note 1. 
10 MARCIA ANGELL, THE TRUTH ABOUT THE DRUG COMPANIES: HOW THEY 
DECEIVE US AND WHAT TO DO ABOUT IT (2005).  See also JOHN ABRAMSON, 
OVERDOSED AMERICA: THE BROKEN PROMISE OF AMERICAN MEDICINE (2008) 
(highlighting the various expenses associated with prescription drugs); SHANNON 
BROWNLEE, OVERTREATED: WHY TOO MUCH MEDICINE IS MAKING US SICKER 
AND POORER (2007) (touching on the costs of pharmaceuticals and health care). 
11 See Select USA: Pharm Industry, supra note 1. 
12 Id. 
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Nordisk A/S, which closes a longstanding loophole whereby brand 
name manufacturers publish overbroad “use codes” that overstate the 
reach of their patents in Food and Drug Administration (FDA) 
regulatory filings, thus preventing generic drug manufacturers from 
supplying the drug at a much cheaper rate.13  Part II investigates the 
historical and regulatory background of pharmaceutical drugs and the 
stages they progress through (from clinical testing to the store 
shelf).14  Part III addresses the major problem that has developed in 
the pharmaceutical industry.  Part IV states the facts of the lawsuit 
between the parties Caraco and Novo, while Part V conducts an in 
depth analysis on Justice Kagan’s majority opinion, followed by 
Justice Sotomayor’s concurring opinion.  Part VI discusses the legal 
effects this case has had on the pharmaceutical industry and some 
possible solutions to the FDA’s current drug approval situation, 
which has proven to be largely inefficient and ineffective.  Part VII 
provides FDA counterarguments to the suggested solutions; and part 
VIII addresses recent FDA and Congressional developments, while 
part IX summarizes and concludes. 
 
II.   HISTORICAL BACKGROUND 
The Food and Drug Administration15 is responsible for regulating 
the manufacture, sale, and labeling of prescription drugs.16  If a 
                                                 
13 132 S. Ct. 1670 (2012). 
14 Id.  
15 The Food and Drug Administration (FDA) is “an agency within the U.S. 
Department of Health and Human Services.”  FDA Fundamentals, U.S. FOOD AND 
DRUG ADMINISTRATION, 
http://www.fda.gov/AboutFDA/Transparency/Basics/ucm192695.htm (last visited 
May 25, 2013).  The agency has an “Office of the Commissioner and four 
directorates overseeing the core functions of the agency: Medical Products and 
Tobacco, Foods, Global Regulatory Operations and Policy, and Operations.”  Id.  
FDA is primarily tasked with protecting the health of the general public by assuring 
the “safety, effectiveness, and security” of various drugs, foods, dietary 
supplements and other various products consumed by human beings.  Id.  FDA is 
also responsible for “protecting the public from electronic product radiation, 
assuring cosmetics and dietary supplements are safe and properly labeled, 
regulating tobacco products, and advancing the public health by helping to speed 
product innovations.”  Id.  “FDA’s responsibilities extend to the 50 United States, 
the District of Columbia, Puerto Rico, Guam, the Virgin Islands, American Samoa, 
and other U.S. territories and possessions.”  Id. 
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company seeks approval from the FDA to sell a new drug, they must 
first test the drug in the laboratory and on animals to determine 
whether the drug is safe enough to be tested on humans.17  The 
company then submits an Investigational New Drug Application 
(IND) to the FDA.  The FDA reviews the IND application and 
determines whether to approve the application for testing on human 
beings.18  Once the IND application is approved, the company will 
initiate a Phase I study to assess the safety of the drug.19  The initial 
testing phase typically lasts for several months and includes a test 
group comprised of 20-to-100 paid volunteers.  Scientists and 
analysts study how the drug is “absorbed, metabolized, and excreted” 
in human beings.20  Phase I also examines the side effects that occur 
from taking the drug and whether the drug increases as higher 
dosages are consumed.21   
Once Phase I is complete and the drug is deemed safe, the 
company will initiate Phase II of the clinical trial, which focuses on 
the efficacy of the experimental drug.22  Phase II involves hundreds 
of human patients and can last anywhere from a couple of months to 
two years.23  Typically Phase II clinical studies are “blind studies” 
                                                 
16 How FDA Evaluates Regulated Products: Drugs, U.S. FOOD AND DRUG 
ADMINISTRATION (Apr. 04, 2012), 
http://www.fda.gov/AboutFDA/Transparency/Basics/ucm269834.htm. The FDA 
uses a series of data and methods to determine whether products are safe for 
consumers.  Id.  
17 Id.  
18 Id.  
19 Overview of Clinical Trials, CENTER WATCH (2012), 
http://www.centerwatch.com/clinical-trials/overview.aspx. 
20 Id.  According to Center Watch’s website: “About 70% of experimental 
drugs pass this phase of testing.”  Id. 
21 Id.  
22 Id.  Although information gathered from “human trials are analyzed by a 
team of experts before a drug is approved, it [is] impossible to anticipate all bad 
reactions—especially very rare safety risks—unless they had also happened with 
use of a similar drug.”  Id.  Further complicating matters is the fact that many of the 
patients selected for the clinical trials are already sick and may be taking other 
drugs simultaneously with the experimental drug.  
23 Id. 
 Journal of the National Association of Administrative Law Judiciary 33-1 348 
that incorporate control groups into the mix.24  Blind studies “allow 
investigators to provide the pharmaceutical company and FDA with 
comparative information about the relative safety and effectiveness 
of the new drug.”25  If the experimental drug completes Phase I and II 
testing, then Phase III begins.  Phase III involves large scale testing 
on hundreds to thousands of human patients and can span several 
years in length.26  “This large-scale testing . . . provides the 
pharmaceutical company and the FDA with a more thorough 
understanding of the effectiveness of the drug . . . the benefits, and 
the range of possible adverse reactions.”27 
 Once Phase III is complete,28 pharmaceutical companies are 
required to compile their clinical testing data and send it to the 
FDA’s Center for Drug Evaluation and Research (CDER) in a New 
Drug Application (NDA).29  An NDA has several components as 
required by 21 U.S.C. § 355 (b)(1), the first being: “(A) full reports 
of investigations which have been made to show whether or not such 
drug is safe for use and whether such drug is effective . . . .”30  The 
report must also contain  
 
(B) a full list of the articles used as components of 
such drug; (C) a full statement of the composition of 
such drug; (D)31 a full description of the methods used 
                                                 
24 Overview of Clinical Trials, supra note 19.  Blind studies “mean that neither 
the patients nor the researchers know who has received the experimental drug.”  Id. 
25 Id.  It is estimated that only one third of experimental drugs successfully 
complete Phase I and Phase II clinical trials.  
26 Id. 
27 Id.  Ultimately the FDA is tasked with evaluating the pros and cons of a drug 
and whether it is safe enough for enough for mass human consumption.  Some of 
the questions they consider are “if the [drug is] good for one person or a small 
group, will it be good for the whole population?  Which safety risks are likely to be 
acceptable to patients who might take a drug and physicians who might prescribe 
it?”  How FDA Evaluates Regulated Products: Drugs, supra note 16.  
28 Approximately “70% to 90% of drugs that enter Phase III studies 
successfully complete this phase of testing.”  Overview of Clinical Trials, supra 
note 18.  
29 How FDA Evaluates Regulated Products: Drugs, supra note 16.  
30 21 U.S.C. § 355 (b)(1) (2012). 
31  This is a statement describing the drug’s components and label, which 
includes what the drug will be used to treat.  
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in, and the facilities and controls used for, the 
manufacture, processing, and packing of such drug.32  
 
It must also contain: “(E) such samples of such drug and of the 
articles used as components thereof as the Secretary may require; (F) 
specimens of the labeling proposed to be used for such drug, and (G) 
any assessments required . . . .”33  In addition to the NDA, the 
manufacturer must also file “the patent number and the expiration 
date of any patent which claims the drug . . .”34 and any other method 
of use claims the manufacturer wishes to assert.35  
Pursuant to 21 C.F.R. § 314.53, brand-name manufacturers must 
provide descriptions of their method-of-use patents.36  These 
descriptions are referred to as “use codes.”  If the FDA approves a 
new brand manufacturer’s drug, the Secretary will then publish the 
information provided in the NDA, such as the patent number, 
expiration of patents, descriptions of method-of-use patents, etc..  
This information is informally known as the Orange Book, but 
officially referred to as the “Approved Drug Products with 
Therapeutic Equivalence Evaluations.”37  Unfortunately, the FDA 
                                                 
32 Id. 
33 21 U.S.C. § 355 (b)(1) (2012). 
34 Id.  This information is part of The Drug Price Competition and Patent Term 
Restoration Act of 1984; Establishment of a Public File and Request for 
Comments, 50 Fed. Reg. 26791–01.  The “Hatch–Waxman amendments” require 
brand name manufacturers to publish this information so that generic drug 
companies would know when the manufacturing patents expire.  21 U.S.C. § 355 
(2012). 
35 21 U.S.C. § 355 (b)(1) (2012).  “The FDA may approve a brand-name drug 
for multiple methods of use—either to treat different conditions or to treat the same 
condition in different ways.”  Caraco Pharm. Laboratories, Ltd. v. Novo Nordisk 
A/S, 132 S. Ct. 1670, 1676 (2012).  The applicant also has the opportunity to 
amend their NDA if they receive a patent after they file the NDA but before the 
FDA approves the application.  See 21 U.S.C. § 355 (b)(1). 
36 See 21 C.F.R. §§ 314.53(c)(2)(ii)(P)(3), (e) (2011).  
37 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1676.  This is list is referred 
to as the “Orange Book” because of “its orange colored cover.”  68 Fed. Reg. 
36676–01 (June 18, 2003). 
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“does not attempt to determine if that information is accurate.”38  
Rather, the FDA assumes the information is completely accurate.39  
Once this process is completed, other companies seeking 
permission to sell a generic version of the drug may do so by filing 
an Abbreviated New Drug Application (ANDA).40  The ANDA has 
several requirements and is specifically designed to expedite low-cost 
generic versions of brand-name drugs into the market, so that more 
people can afford to use the drug.41  Instead of conducting 
independent studies to obtain evidence on the generic drug’s safety 
and efficacy, ANDA applicants will typically show that the generic 
drug has the same active ingredients and is “biologically equivalent 
to the brand-name drug.”42  ANDA applicants will also demonstrate 
“that the conditions of use prescribed, recommended, or suggested in 
the labeling proposed for the new drug have been previously 
approved for a [listed drug].”43  FDA is prohibited from approving an 
ANDA application that would infringe on a patent, and thus the 
timing of when a generic drug will be approved is based on the 
“scope and duration” of patents in place for the brand-name drug.44  
As discussed prior, there are two types of patents: (1) that protects 
the actual drug compound; and (2) that protects the brand 
manufacturer’s rights to a specific method-of-use.45   
                                                 
38 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1676.  The FDA 
“determined that it is more efficient and accurate to ask the NDA holder to give us 
the exact use code description to be published in the Orange Book.”  68 Fed. Reg. 
36676–01 (June 18, 2003). 
39 Id. 
40 See 21 U.S.C. § 355 (j)(2)(A) (2012).  
41 Previously recognized in Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661, 
676 (1990). 
42 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1676. 
43 21 U.S.C. § 355 (j)(2)(A)(i).  This is basically a short cut to getting the 
FDA’s approval.  A “listed drug” means that it has already been published in the 
FDA’s Orange Book and has already received FDA approval, meaning it has gone 
through all the required testing phases.  Id. 
44 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1676.  The FDA cannot 
approve an ANDA application for a generic version of a drug if the brand name 
company still holds a valid patent on the drug compound.  Id.  
45 Id.  The method-of-use patent can continue long after the drug compound 
patent has expired (A drug compound patent usually lasts between five and 
fourteen years.). 
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After the generic company consults the Orange Book, they must 
file the ANDA and convince the FDA that its generic drug will not 
infringe on any of the brand-name drug manufacturer’s patents.46  In 
the case where all of the brand-name drug manufacturer’s patents 
have expired (or will expire prior to the generic drug’s approval) or 
are not listed in the Orange Book, the generic drug manufacturer 
simply states that information, and the ANDA is approved.47 
If the brand-name manufacturer’s patents have not yet expired, 
there are two methods of certification the generic manufacturer can 
pursue.  The first option is that the generic company can submit a 
section viii (“section viii”) statement asserting that they will market 
the drug for one or more methods that are not covered by the brand 
name drug company’s patents.48  Typically a generic drug company 
will file a section viii statement when the brand-name drug 
company’s drug compound patent has expired, and only a method-of-
use patent still exists.49  If the generic drug company elects to pursue 
a section viii route, they will propose, “labeling for the generic drug 
that ‘carves out’ from the brand's approved label the still-patented 
methods of use.”50  The FDA will under no circumstances approve an 
ANDA if the generic brand’s modified label overlaps with any of the 
brand name’s use code.51  As mentioned prior, the FDA assumes the 
brand’s use code accurately describes the methods-of-use and does 
not conduct its own independent research to confirm any of this 
                                                 
46 Id. 
47 See 21 U.S.C. §§ 355(j)(2)(A)(vii)(I)–(III) (2012). 
48 See 21 U.S.C. § 355(j)(2)(A)(viii) (2012). 
49 See supra note 33–35. 
50 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1677.  The expression 
“carved out” refers to removing patented methods of use from the new modified 
label that the generic drug company is proposing.  The FDA is allowed to approve 
a generic drug’s modified version of the brand name’s label (as long as it does not 
include patented methods-of-use), which is an exception to the normal rule that 
states a generic drug label must have the same label as the brand name.  See 21 
U.S.C. §§ 355(j)(2)(A)(v), (j)(4)(G) (2012).  
51 See Applications for FDA Approval to Market a New Drug: Patent 
Submission and Listing Requirements, 68 Fed. Reg. 36676, 36682–83 (June 18, 
2003).  There can be absolutely no overlap of the generic drug’s label with the 
brand name company’s label if the brand name company still has a valid patent on 
a method for using the drug.  
 Journal of the National Association of Administrative Law Judiciary 33-1 352 
information.52  Thus, whether section viii is available to a generic 
drug company hinges on how the brand name drug company 
describes its various patents.53  Interestingly, if the FDA determines 
there is enough space for the generic manufacturer’s proposed label, 
then it will approve the ANDA application.54 
The second option for a generic drug manufacturer is that it can 
choose to file a paragraph IV (“paragraph IV”) certification, which in 
essence provides the patent is “invalid or will not be infringed by the 
manufacture, use, or sale of the [generic] drug.”55  A generic drug 
manufacturer will choose to file a paragraph IV certification in two 
scenarios.  The first scenario is if the company wants to market and 
sell the generic drug for all purposes, instead of “carving out” the 
options that are still “supposedly” under patent.56  The second 
scenario is if the generic drug manufacturer is unable to avoid an 
overlap with the brand name company’s use code, despite having 
carved out various uses.57  Filing a paragraph IV certification leaves 
the generic brand company vulnerable to litigation because the patent 
                                                 
52 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1677.  According to the 
FDA, it “lacks ‘both [the] expertise and [the] authority to review patent claims; 
although it will forward questions about the accuracy of a use code to the brand, its 
own ‘role with respect to patent listing is ministerial.’”  Applications for FDA 
Approval, 68 Fed. Reg. at 36683 (June 18, 2003).  This creates a vicious ineffective 
circle for drug approval.  Basically, the brand manufacturer submits a description 
claiming a particular approved use for the drug, and the FDA in turn sends the 
description back to the brand company and asks that they make sure the description 
is accurate.  The FDA is essentially asking the brand manufacturers to police the 
accuracy of their own use code descriptions.  A brand manufacturer submitting an 
overbroad use code so that a generic form of the drug cannot be produced is never 
going to openly admit to FDA that their use code is overly broad and inaccurate.  
Furthermore, the FDA believes “its scarce resources would be better utilized in 
reviewing applications rather than reviewing patent claim.”  Abbreviated New 
Drug Application Regulations: Patent Exclusivity Provisions, 59 Fed. Reg. 50,338, 
50,343 (Oct. 3, 1994). 
53 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1677. 
54 Id.  
55 21 U.S.C. § 355(j)(2)(A)(vii)(IV) (2012).  Filing a paragraph IV certification 
can almost guarantee that the brand name company will sue the generic company 
for patent infringement.  See infra note 51.  
56 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1677. 
57 Id.  See supra note 50 for explanation of “carving out.”  
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statute58 considers the filing of a paragraph IV certification to be an 
act of infringement, giving the brand name company a valid cause of 
action.59  If the brand manufacturer chooses to file a lawsuit against 
the generic manufacturer for filing a paragraph IV certification,60 the 
FDA may not approve the generic company’s ANDA for up to thirty 
months or until a final judgment on the lawsuit has been entered.61  
Filing a paragraph IV certification has both pros and cons because 
although it exposes the generic company to potential litigation, the 
end result could allow the generic drug manufacturer to sell its drug 
for all uses approved by the FDA.62 
 
III.   THE PROBLEM 
At the end of the 20th century, evidence began to surface that 
numerous brand name drug companies were exploiting the statutory 
structure in order to prevent generic drug companies from certifying 
their drug, or at least significantly delaying the drug’s appearance on 
the pharmaceutical market.63  Sure enough, the Federal Trade 
Commission (FTC) published a study detailing these practices in July 
of 2002.64  The FTC study focused its attention on brand name drug 
                                                 
58 The “patent statute” is 35 U.S.C. § 271, and explains when a patent is 
considered to be infringed upon and the available and appropriate courses of action.  
See generally 35 U.S.C. § 271 (2010). 
59 See 35 U.S.C. § 271(e)(2)(A).  “It shall be an act of infringement to submit 
an application under section 505(j) of the Federal Food, Drug, and Cosmetic Act . . 
. for a drug claimed in a patent or the use of which is claimed in a patent.”  Id.  The 
valid cause of action in this situation will be a lawsuit against the generic 
manufacturer for infringing a valid patent.  
60 If a generic company files a paragraph IV certification, the brand name 
company has forty-five days to bring an action for infringement against the party.  
Id.  
61 See 21 U.S.C. § 355(j)(5)(B)(iii) (2012). 
62 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1677–78. 
63 Id.  
64 General Drug Entry Prior to Patent Expiration: An FTC Study, FEDERAL 
TRADE COMM’N (July 2002), available at 
http://www.ftc.gov/os/2002/07/genericdrugstudy.pdf [hereinafter FTC Study].  The 
Hatch–Waxman Amendments to the Federal Food Drug and Cosmetic Act 
substantially altered the way in which generic drugs receive market approval from 
the FDA.  The Hatch–Waxman Amendments helped speed up the procedures for 
allowing generic drugs to be sold on the open market, and without a doubt greatly 
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manufacturing companies that were submitting inaccurate patent 
information to the FDA, in order to prevent generic drugs from 
coming to market.65  In Mylan, a brand name drug manufacturer had 
listed a new patent just prior to the expiration of their original drug 
compound patent.66  The new patent did not cover the drug’s 
compound or its method of uses, however the brand name drug 
manufacturer was still able to extend its rights over the drug.67  The 
generic manufacturer sued the brand name manufacturer and wanted 
them to remove their improper description listed in the Orange Book.  
However, the Federal Circuit Court of Appeals found that the Hatch-
Waxman Amendments did not provide for this type of solution.68  
The FTC found, that as a result of the ruling in Mylan, generic 
manufacturers in Mylan’s predicament only had one option, which 
was to file a paragraph IV certification and wait for the thirty-month 
waiting period to expire.69  Once thirty months had expired, the FDA 
could approve the ANDA.70  
                                                 
increased the amount of generic drugs in the market.  Id.  In fact, at the time the 
FTC finished conducting their study in 2002, they reported that generic drugs 
comprised more than forty seven percent of the prescriptions filled in the U.S., 
which was an enormous increase from nineteen percent in 1984 when Hatch–
Waxman was first implemented.  Id.  Despite Hatch–Waxman’s success, there were 
several provisions in the act that allowed for certain strategies to be used by brand 
name pharmaceutical manufacturers to hinder the availability of generic drugs.  Id.  
The FTC study in 2002 took on the task of investigating whether the publication of 
overbroad use patents by brand name pharmaceutical manufacturers represented 
more isolated instances, or typical measures taken by manufacturers to ensure a 
generic form of the drug could not be brought to market.  Id. 
65 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1678.  The FDA was 
treating the patent information submitted to them as true and correct; they never 
conducted any independent due diligence to ensure the descriptions were accurate.  
Id. 
66 See Mylan Pharm., Inc. v. Thompson, 268 F.3d 1323 (Fed. Cir. 2001). 
67 Id.  The Federal Circuit in Mylan found that delisting the patent (removing 
the patent completely) was not a proper remedy under the Hatch–Waxman 
Amendments.  Id.  However, the decision in Mylan alerted Congress to a major 
problem.  Id.  Generic companies basically had no way of challenging inaccurate 
patent listings, thus the FDA was unable to approve applications for a generic form 
of the drug.  Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1687. 
68 Mylan Pharm., Inc., 268 F. 3d at 1323.  
69 See FTC Study, supra note 64, at 41–45.  
70 Id. 
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In response to this abuse, Congress created a legal counterclaim 
for generic drug manufacturers to contest incorrect and overbroad 
patent information that brand name manufacturers submit to the 
FDA.71  Congress passed the Medicare Prescription Drug, 
Improvement, and Modernization Act of 2003, which allows generic 
drug manufacturers to: 
 
assert a counterclaim seeking an order requiring the 
[brand manufacturer] to correct or delete the patent 
information submitted . . . on the ground that the 
patent does not claim either -- (aa) the drug for which 
the application was approved or (bb) an approved 
method of using the drug.72   
 
Essentially, the counterclaim allows a generic drug manufacturer 
to obtain a judgment in their favor, instructing the brand name drug 
manufacturer to “correct or delete” their overbroad or incorrect 
description regarding the patent, which is preventing FDA from 
certifying the generic manufacturer’s drug.73 
 
IV.   FACTS 
The petitioner seeks to sell and the respondent sells the popular 
diabetes drug repaglinide,74 which is commonly used to treat type 
two diabetes.75  Repaglinide is a pharmaceutical drug that helps 
                                                 
71 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1678.  
72 21 U.S.C. § 355(j)(5)(C)(ii)(I) (2012).  See also Medicare Prescription Drug, 
Improvement, and Modernization Act of 2003, Pub. L. No. 108–173 (2003).  The 
Medicare Prescription Drug, Improvement, and Modernization Act is a federal law 
that was enacted in 2003; its primary purpose was to help make prescription drugs 
more affordable for Americans, especially for senior citizens. 
73 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1678. 
74 Consumer Medication Information: Repaglinide, U.S. NATIONAL LIBRARY 
OF MEDICINE (Apr. 15, 2011), 
http://www.ncbi.nlm.nih.gov/pubmedhealth/?term=repaglinide. 
75 Type two diabetes is the most common form of diabetes, and millions of 
Americans suffer from this condition.  American Diabetes Association: Type 2, 
AMERICAN DIABETES ASSOCIATION, http://www.diabetes.org/diabetes-basics/type-
2/ (last visited May 25, 2013).  Type two diabetes is a condition where the body is 
unable to produce enough insulin.  Id.  Insulin is essential to the human body 
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balance the amount of glucose (sugar) in the human body.76  It works 
to decrease the overall amount of glucose in the blood by stimulating 
the release of insulin from the pancreas.77  Novo, respondent in this 
case, manufactures the brand name version of repaglinide called 
Prandin.78  The FDA approved three uses for Prandin in order to treat 
type two diabetes: “repaglinide by itself; repaglinide in combination 
with metformin; and repaglinide in combination with 
thiazolidinediones (TZDs).”79  Novo is a worldwide leader in 
diabetes care and obtained the original patent over the repaglinide 
drug compound, “known as the ‘035 patent.”80  Their drug compound 
patent expired in 2009, but in 2004 Novo obtained a method-of-use 
patent for repaglinide to be used in combination with metformin 
(“‘358 patent”), which does not expire until 2018.81  Novo only held 
one patent for the three FDA approved methods of use for 
repaglinide at the time the Supreme Court granted certiorari.82 
 Caraco, petitioner in this case, seeks to sell a generic version of 
the drug repaglinide for two of the three above-mentioned purposes.83  
In 2005 the company filed an ANDA with the FDA so that they 
could sell a generic brand version of repaglinide.84  At this time, 
                                                 
because it helps the body use glucose for energy.  Id.  When you consume food, the 
body breaks down all of the sugars and starches into glucose for the body’s cells to 
use as energy.  Id.  Insulin helps get the sugar from the blood into the cells.  Id.  
Serious problems arise when there is a build up of glucose in the blood.  Id.  
76 Consumer Medication Information: Repaglinide, U.S. NATIONAL LIBRARY 
OF MEDICINE (Apr. 15, 2011), 
http://www.ncbi.nlm.nih.gov/pubmedhealth/?term=repaglinide. 
77 Id.  The pharmaceutical drug comes in a tablet form and is usually ingested 
thirty minutes before or after a meal.  Id. 
78 Id. 
79 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1678. 
80 Id. 
81 Id.  Novo’s ‘358 patent is the patent at issue in this case and “claims a 
method for treating diabetes by administering . . . repaglinide in combination with 
metformin.”  Id. 
82 Id. at 1679.  At the time certiorari was granted by the Supreme Court, Novo 
held no patent for the use of repaglinide with thiazolidinediones or its use alone.  
Id.  
83 Id. 
84 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1679.  In 2005, when 
Caraco filed its ANDA, “Novo's use code for the ‘358 patent represented that the 
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Novo held a patent on the drug compound for Prandin, which was 
listed as patent ’035 as well as a method-of-use patent for Prandin’s 
use with metformin, which was listed as patent ‘358.85  At the time 
Novo filed the ANDA, they informed the FDA that they would not 
market their new generic form of the drug until after the drug 
compound patent ‘035 had expired in 2009.86  As for the remaining 
‘358 patent, Caraco filed a paragraph IV certification stating that 
patent ‘358 was “invalid or would not be infringed [upon].”87  As 
soon as Caraco filed their ANDA application and paragraph IV 
statement, Novo treated the filing as an infringement on the ‘358 
patent and immediately initiated a lawsuit against Caraco.88 
The FDA advised Caraco that if they were not planning on 
marketing the drug repaglinide for the use with metformin, it should 
submit a section viii statement instead, which would allow Caraco to 
sell the drug for the other two uses of repaglinide that were not 
patented by Novo.89  Caraco took the FDA’s advice and filed a 
section viii statement in 2008, and carved out90 the patented method-
of-use from their generic drug’s label.91  However, right before the 
FDA approved Caraco’s section viii filing, Novo changed its use 
code description for the ‘358 patent, which described “a method for 
improving glycemic control in adults with type two diabetes.”92  The 
newly altered code indicated that Novo’s ‘358 patent protected all 
three methods-of-use for repaglinide that were approved by the FDA 
to treat diabetes, making Caraco’s carved out label of uses 
insufficient.93  Caraco’s label now overlapped with Novo’s use code 
on two of the uses approved by the FDA; Caraco was unable to carve 
                                                 
patent covered ‘use of repaglinide in combination with metformin to lower blood 
glucose.’”  Id. 
85 Id. 
86 Id. 
87 21 U.S.C. § 355(j)(2)(A)(vii)(IV) (2012). 
88 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1679.  
89 Id. 
90 Id.  In 2008, Novo still had a patented method of use for repaglinide and 
metformin to be used together.  See also supra note 50 explaining “carving out.” 
91 Id. 
92 Novo Nordisk A/S v. Caraco Pharm. Laboratories, Ltd., 601 F.3d 1359, 
1363 (Fed. Cir. 2010). 
93 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1679. 
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out these two uses because, if they did, there would be no other uses 
left to market or sell.94  As mentioned prior, the FDA had only 
approved repaglinide for three uses, all of which were encompassed 
by Novo’s newly updated use code patent ‘358.95  As a result of 
Novo’s updated use code description, the FDA informed Caraco that 
it could no longer file a section viii statement seeking market 
approval for their generic drug.96 
Caraco immediately responded to Novo’s infringement lawsuit 
by filing a statutory counterclaim against them.97  “The counterclaim 
sought an order98 requiring Novo to ‘correct’ its use code ‘on the 
grounds that the ‘358 patent does not claim’99 two approved methods 
of using repaglinide—alone and in combination with TZD’s.”100  The 
U.S. District Court for the Eastern District of Michigan ruled in favor 
of Caraco, thus granting their motion for summary judgment.101  The 
District Court found that “Novo [had] improperly filed with the FDA 
for listing in the Orange Book the use code narrative for the method 
of use of the [‘358] patent.”102  Therefore, “Caraco was entitled to a 
mandatory injunction requiring Novo to request FDA to delist [its 
new listing,] and reinstate its former . . . listing.”103  Despite the 
District Court’s ruling, the U.S. Federal Circuit Court of Appeals 
found that “Caraco Pharmaceutical Laboratories, Ltd. does not have a 
statutory basis to assert a counterclaim requesting such injunctive 
                                                 




98 The order sought by Caraco “would permit the FDA to accept Caraco's 
proposed carve–out label and approve the company's ANDA.”  Caraco Pharm. 
Laboratories, Ltd., 132 S. Ct. at 1679. 
99 See 21 U.S.C. § 355(j)(5)(C)(ii) (2012). 
100 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1679.  The counterclaim 
would permit the FDA to approve Caraco’s ANDA and carved out label. 
101 Id. 
102 Novo Nordisk A/S v. Caraco Pharm. Laboratories, Ltd., 656 F. Supp. 2d 
729, 730 (E.D. Mich. 2009).  The district court’s ruling would have forced Novo to 
delist its new patent description and reinstate its former patent description, thus 
allowing Caraco to file its section viii. 
103 Id. 
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relief,” and therefore it reversed and vacated the injunction.104  The 
Federal Circuit Court of Appeals analyzed 21 U.S.C. § 355, which 
allows for a generic company to file a counterclaim.  The statute 
states that: “ANDA applicant may assert a counterclaim seeking an 
order requiring the holder to correct or delete the patent information . 
. . on the ground that the patent does not claim either (aa) the drug for 
which the applicant was approved or (bb) an approved method of 
using [it].”105 
The Federal Circuit Court of Appeals interpreted the information 
in (bb) to mean that Caraco was required to demonstrate that “the 
‘358 patent [did] not claim any approved method of use.”106  The 
Federal Circuit reiterates that a counterclaim can only be authorized 
if the “listed patent does not claim any approved methods of using 
the listed drug.”107  They held that because Novo’s patent covered 
one method-of-use (repaglinide with metformin), the statutory 
counterclaim was unavailable to Caraco.108  The court also ruled that 
the “counterclaim provision does not reach use codes because they 
are not ‘patent information submitted by the [brand] under subsection 
(b) or (c).’”109  Caraco filed a writ of certiorari with the United States 
Supreme Court, which was granted on June 27, 2011.110 
                                                 
104 Novo Nordisk A/S v. Caraco Pharm. Laboratories, Ltd., 601 F.3d 1359, 
1360 (Fed. Cir. 2010).  
105 See 21 U.S.C. § 355 (j)(5)(C)(ii)(I) (2012). 
106 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1679.  The Federal Circuit 
Court found that “[a]n approved method means any approved method.”  Id. at 
1680.  Since “the patent covers one approved method of use—repaglinide in 
combination with metformin—the counterclaim was unavailable [to Caraco].”  Id. 
107 Novo Nordisk A/S, 601 F.3d at 1365. 
108 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1680. 
109 Id.  The Federal Circuit believed the patent information submitted consists 
only of the patent number and expiration date.  Id.  Judge Dyk disagreed and wrote 
a dissenting opinion.  Dyk “would have read the phrase ‘the patent does not claim . 
. . an approved method of using the drug’ to include situations where, as here, the 
use code wrongly indicates that the patent covers one or more particular approved 
methods of use.”  Id. (Dyk, J., dissenting).  Furthermore, “he would have construed 
‘patent information submitted . . . under subsection (b) or (c)’ to include use 
codes.”  Id. (Dyk J., dissenting).  Ultimately, the Supreme Court granted certiorari 
and sided with Judge Dyk.   
110 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1680.  First, the Supreme 
Court was tasked with deciding when a “patent does not claim . . . an approved 
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V. ANALYSIS OF OPINION 
A. Judge Kagan’s Majority Opinion 
Recognizing the importance of the statutory language in 21 
U.S.C. § 355, Justice Kagan’s opinion begins with an analysis of two 
statutory phrases against the backdrop of a third statutory phrase.111  
After a thorough review of the statutory language, Justice Kagan 
determined that the “statute permits a counterclaim whenever a 
patent does not claim a method of use for which the ANDA applicant 
seeks to market the drug.”112  She also determined that the 
counterclaim provides a way to correct the overbroad use codes by 
deleting or correcting the use code description.113  Next, Justice 
Kagan addressed and dismissed Novo’s claim that the Court would 
be resurrecting a bill that Congress previously did not support, as 
Congress failed to pass S. 812,114 which would have allowed a 
                                                 
method of using’ a drug.  Second, [the Court had to] determine the content of 
patent information submitted . . . under subsection (b) or (c) of § 355.”  Id. 
111 Id.  The third statutory phrase is the remedy for a prevailing 
counterclaimant, which is to either “correct or delete” the inaccurate patent.  Id.  
When the Supreme Court conducts statutory interpretations, they take into 
consideration several factors, such as the language of the statute itself, the context 
the language is being used in, and the broader context of the statute as a whole.  See 
Robinson v. Shell Oil Co., 519 U.S. 337 (1997).   
112 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1683.  In her opinion, 
Justice Kagan conceded that the counterclaim clause of the Medicare Prescription 
Drug, Improvement, and Modernization Act of 2003 was confusing and not 
entirely clear.  However, when the Court considered the statutory text and context 
together, they concluded, “a generic manufacturer in Caraco's position can use the 
counterclaim.”  Id. at 1681. 
113 Id. at 1684. 
114 Greater Access to Affordable Pharmaceuticals Act of 2002, S. 812, was a 
Congressional Senate Bill sponsored by Senator Charles Schumer and was 
introduced on May 1, 2001.  Greater Access to Affordable Pharmaceuticals Act of 
2002, S. 812, 107th Cong. (2002).  S. 812 would have required pharmaceutical 
companies to register their patents with the FDA within thirty days of approval and 
would have allowed a generic company to challenge an overbroad patent 
description by filing a separate civil action.  Id. at 8.  The bill also would have 
allowed for the importation of prescription drugs into the United States from 
Canada.  Id.  The bill was never enacted into law.  Id. 
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generic company to challenge an overbroad patent description.115  
Finally, Justice Kagan and the Court rejected the argument that 
Congress enacted the counterclaim only to solve problems similar to 
those in Mylan.116  Justice Kagan and the Court ultimately decided 
that Caraco was allowed to bring a counterclaim, which requested 
Novo to correct its use code on the ground that the patent did not 
claim an approved method of use for the drug.117 
 
1. A Company May Bring a Counterclaim to Show That a 
Method of Use is Unpatented. 
A company that submits an ANDA application to the FDA and is 
subsequently sued for patent infringement may bring a counterclaim 
“on the ground that the patent does not claim an approved method of 
using the drug.”118  Both Caraco and Novo debate the true meaning 
of this language, with each interpretation resulting in a drastically 
different outcome.119  Novo argues that “not an” means “not any,” 
which means the counterclaim would only be available if the patent 
does not claim any approved method for using the drug.120  If this 
were the true meaning, Caraco would be unable to bring a 
counterclaim against Novo because Novo’s ‘358 patent claims the 
use of repaglinide with metformin.121  Unsurprisingly, Caraco 
advocates for a different interpretation and takes “not an” to mean 
“not a particular one,” meaning the statute allows for a counterclaim 
whenever the ANDA applicant does not seek to market the drug 
under a method of use already claimed by another company’s 
patent.122  Caraco’s view would allow for use of the counterclaim 
because “Novo’s ‘358 patent does not claim the use of repaglinide 
with TZDs or its use alone.”123  The Supreme Court engages in a 
                                                 
115 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1684. 
116 See infra notes 168–72. 
117 See infra notes 181–83. 
118  Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1681. 
119 Id. 
120 Id. 
121 Id.  
122 Id.  
123 Id.  
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comical analysis of what “not an” means and ultimately sides with 
Caraco’s interpretation.124 
The Court explained that an approved drug might have multiple 
uses, not all of which are covered by a patent.125  The Hatch-Waxman 
Amendments permits the FDA to approve applications for companies 
that wish to market generic forms of drugs for unpatented uses.126  
Essentially, the statutory scheme envisions that a patented use for a 
particular drug will not bar the marketing of a generic form for an 
unpatented use.127  Generic manufacturers use the counterclaim to 
challenge an overbroad assertion of rights by brand name 
manufacturers.128  Thus, the Court found that the “availability of the 
counterclaim matches the availability of FDA approval under the 
statute: A company may bring a counterclaim to show that a method 
of use is unpatented because establishing that fact allows the FDA to 
authorize a generic drug via section viii.”129 
                                                 
124 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1681.  The Supreme Court 
took the position that the answer to the question “what does not an mean?” is “it 
depends.”  The Court strongly believes that context determines the meaning of 
words, and gives various everyday life scenarios to demonstrate this.  Id. 
Sometimes “not an” means “not any.”  Id.  “If your spouse tells you he is late 
because he ‘did not take a cab,’ you will infer that he took no cab at all (but took 
the bus instead).”  Id.  Furthermore, “if a sports-fan friend bemoans that ‘the New 
York Mets do not have a chance of winning the World Series,’ you will gather that 
the team has no chance whatsoever (because they have no hitting).”  Id.  However, 
the Court points out that other times “not an” means “not a particular one.”  Id.  
“Suppose your spouse tells you that he got lost because he ‘did not make a turn.’  
You would understand that he failed to make a particular turn, not that he drove 
from the outset in a straight line.”  Id.  Furthermore, “suppose your child explains 
her mediocre grade on a college exam by saying that she ‘did not read an assigned 
text.’  You would infer that she failed to read a specific book, not that she read 
nothing at all on the syllabus.”  Id.  The Court comically communicates that 
CONTEXT MATTERS! 
125 Id.  An approved drug may have multiple uses.  See, e.g., 21 U.S.C. § 
355(b)(1) (2012) (requiring that an NDA applicant file information about “any 
patent which claims the drug . . . or which claims a method of using such drug”).  
Id. 
126 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1681.  In other words, the 
statutory scheme “contemplates that one patented use will not foreclose marketing 
a generic drug for other unpatented ones.”  Id. at 1682. 
127 Id. 
128 Id. at 1681. 
129 Id.  
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The Court highlights that under section 355, the FDA could 
approve Caraco’s ANDA application so long as Novo does not 
possess a patent covering the uses listed in Caraco’s ANDA 
application.130  However, Novo argues that since they have a valid 
patent on one of the three approved uses, Caraco’s counterclaim 
disappears; the Court completely disagrees with Novo’s position.131  
Novo further argues that Congress could have “imposed additional . . 
. qualifications on the term ‘an approved method of use’ and indeed 
did so in another place in the statute.”132  The Court responds by 
saying the mere possibility that Congress could have provided clearer 
phrasing does not outweigh the natural reading of the statute.133  If 
this were true, courts today would interpret most of the statutes 
passed by Congress in a much different way.134  However, the Court 
does not wish to focus on the possibility that Congress could provide 
clearer language in the statute, rather it believes the words “not any” 
do not appear in the counterclaim provision because Congress did not 
                                                 
130 Id.  If Caraco does not try to patent a use already claimed by Novo, then the 
FDA could approve Caraco’s ANDA application “regardless whether a patent 
protects yet a third method of using the drug.”  Id.  Novo even “agrees that Caraco 
could bring a counterclaim if Novo's assertion of patent protection for repaglinide 
lacked any basis—for example, if Novo held no patent, yet claimed rights to the 
pair of uses for which Caraco seeks to market its drug.”  Id. 
131 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1681. 
132 Id. at 1682.  Novo points to “section viii itself, which applies when the 
brand's patent ‘does not claim a use for which the ANDA applicant is seeking 
approval.’”  Id.  See 21 U.S.C. § 355(j)(2)(A)(viii) (2012). 
133 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1682.  The Supreme Court 
elaborates and said that if the possibility of clearer phrasing could outweigh the 
statute’s most natural reading, then courts would interpret most statutes today much 
differently.  They also turn Novo’s argument around on itself and highlight that 
“Congress could have more clearly expressed Novo’s proposed meaning in the 
easiest of ways—by adding a single letter to make clear that ‘not an’ really means 
‘not any.’”  Furthermore, Congress used a “not any” in the very next subclause.  
See 21 U.S.C. § 355(j)(5)(C)(ii)(II) (“Subclause (I) does not authorize the assertion 
of a claim . . . in any [other] civil action.”).  The Court believes Congress knew 
how to say “not any” and would have used the word “not any” if that was the 
meaning they intended, and that this “sees, raises, and bests Novo’s argument.”  
Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1682. 
134 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1682. 
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intend what Novo wishes they had.135  Instead, the Court believes 
that Congress intended the counterclaim provision of the Hatch-
Waxman Amendments to fit within the overall statutory scheme.136  
Fitting into the overall statutory scheme would mean that Congress 
created the counterclaim in order to assist in the approval of non-
infringing generic drugs by the FDA.137 
 
2. Patent Information Submitted Under 21 U.S.C. §§ 355 (b), (c) 
Includes Use Codes. 
Next, Novo argues that Caraco’s counterclaim fails for another 
reason because the counterclaim is unable to provide a way “to 
correct use codes because they are not ‘patent information’ submitted 
by the brand under subsection (b) or (c) of [U.S.C] § 355.”138  The 
Court addresses the first part of Novo’s contention by highlighting 
that although the statute does not define “patent information,” a use 
code must still qualify.139  The statute does require a company (Novo 
in this situation) to describe the method-of-use claimed in their 
patent.140  The Court finds this to be sufficient to fit under the 
                                                 
135 Id.  Novo wishes that Congress had intended to use the words “not any” 
because that would mean the FDA would be unable to approve Caraco’s ANDA 
application because Novo holds a valid patent over one of the approved uses.  Id.  
If Novo’s reading of the statute were true, the FDA would only be able to approve 
Caraco’s application if Novo did not have one single valid patent.  Id. 
136 Id. 
137 Id. at 1683.  
138 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1683.  The Court once 
again disagrees with Novo’s argument and sides with Caraco.  Id. 
139 Id. 
140 Id.  See 21 C.F.R. § 314.53(c)(2)(ii)(P)(1)(2)(3), which requires a company 
to include in its published information regarding its patent: 
 
Information on each method-of-use patent including the 
following: (1) Whether the patent claims one or more approved 
methods of using the approved drug product and a description of 
each approved method of use or indication and related patent 
claim of the patent being submitted; (2) Identification of the 
specific section of the approved labeling for the drug product that 
corresponds to the method of use claimed by the patent 
submitted; and (3) The description of the patented method of use 
as required for publication.  
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ordinary understanding of the language, and it is the “submitted 
under” phrase that presents the more difficult question.141  21 U.S.C. 
§ 355 (b), (c), “require an NDA applicant to submit specified 
information: ‘the patent number and the expiration companies to 
submit use codes.142  The Court gives “under” a broad meaning in 
finding that “use codes fall within the counterclaim’s ambit if the 
phrase ‘submitted under’ reaches filings that not only subsections (b) 
and (c) themselves, but also their implementing regulations 
require.”143  The date of any “patent claiming the drug or a method of 
its use.”144  Novo contends only that information accompanies the 
counterclaim provision.145  However, both (b) and (c) of section 355 
oversee the regulatory process in which brand name companies 
provide additional patent information to the FDA, prior to and after 
the approval of an NDA.146  Specifically, those subsections require 
brand Court believes the scope of the term “under” becomes 
principally clear when compared with other phrases such as 
“described in” and “prescribed by,” which appear in neighboring 
                                                 
Id.  
141 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1683. 
142 Id.  The FDA’s principal legal authority was section 505 of the Food Drug 
and Cosmetic Act and 68 Fed. Reg. 36697–36698, which defines the FDA’s 
general rulemaking authority.  
143 Id.  Several Supreme Court cases support giving the word “under” a broad 
meaning.  See Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661 (1990), in which the 
Court examined a similar statutory reference under 35 U.S.C. § 271(e)(1) that 
discussed “submission of information under a Federal law which regulates the 
manufacture, use, or sale of drugs.”  Caraco Pharm. Laboratories, Ltd., 132 S. Ct. 
at 1683.  The Court found that submitting information under a ‘Federal Law’ 
“suggests doing so ‘in furtherance of or compliance with a comprehensive scheme 
of regulation.’”  Id. at 1684 (citing Eli Lilly, 496 U.S. at 667).  The Court in Caraco 
too believes that “[p]atent information submitted . . . under subsection (b) or (c)” 
most naturally refers to patent information provided as part of the “comprehensive 
scheme of regulation” premised on those subsections.  Id.  Also in Ardestani v. 
I.N.S., 502 U.S. 129, 131 (1991), the Court held that a “regulatory proceeding 
‘under section 554,’. . . meant any proceeding ‘subject to,’ ‘governed by,’ or 
conducted ‘by reason of the authority of’ that statutory provision.”  Id.   
144 Id. 
145 Id. 
146 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1683. 
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provisions.147  These phrases typically signify a patent number and 
expiration date.  The Supreme Court contrasts this with the word 
“under,” which they believe naturally “reaches beyond [the] most 
barebones information of [a patent number and expiration date] to 
other patent materials the FDA demands in the regulatory 
process.”148 
The Court found that Congress’s decision once again fits the 
broader statutory context, as use codes are crucial to the 
implementation of the Hatch-Waxman Amendments.149  
Furthermore, use codes are no less important because an FDA 
regulation rather than a statute requires their submission.150  The 
Hatch-Waxman Amendments helped speed the process by which a 
generic drug could be brought to market by requiring FDA to 
approve an ANDA application that is filed with a section viii 
statement, when a company seeks to market a generic form of a drug 
for unpatented methods of use.151  In order for the FDA to determine 
whether a patent covers a specific method of use, they refer to the 
“Orange Book,” which contains all the use codes submitted by drug 
companies during the regulatory process of bringing their drug to 
market.152  The Court points out that if the use codes submitted to 
FDA and published in the “Orange Book” are overly broad, it 
prevents FDA from approving ANDAs.153 
 
                                                 
147 Id.  An example of these different phrases can be found in 21 U.S.C. 
§355(d)(6) (2012).  
148 Id. 
149 Id.  The FDA explains how “[u]se codes are intended to alert ANDA and 
505(b)(2) applicants to the existence of a patent that claims an approved use.  They 
are not meant to substitute for the applicant's review of the patent and the approved 
labeling.”  68 Fed. Reg. 36676–01 (June 18, 2003). 
150 See 68 Fed. Reg. 36676–01 (June 18, 2003), which states that “[u]se codes 
are intended to alert ANDA and 505(b)(2) applicants to the existence of a patent 
that claims an approved use.”  Id. 
151 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1684. 
152 Id. 
153 Id.  “An overbroad use code . . . throws a wrench into the FDA's ability to 
approve generic drugs as the statute contemplates.  So it is not surprising that the 
language Congress used in the counterclaim provision sweeps widely enough to 
embrace that filing.”  Id. 
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3. The Counterclaim Does Provide Remedies for Incorrectly 
Published Use Codes. 
As mentioned prior, Novo contends that the counterclaim does 
not provide a way in which to correct overbroad use codes.154  
Section 355 clearly states that an “applicant [may] assert a 
counterclaim seeking an order requiring the [holder] to correct or 
delete the patent information.”155  The Court interprets the statute to 
provide for two remedies: a brand company may either (1) correct or 
(2) delete its incorrect patent information from the Orange Book.156  
Novo argues that the counterclaim is purely a delisting provision and 
can only “correct erroneous patent numbers.”157  Novo provides the 
Court with an example: if Novo mistakenly listed their patent number 
as ‘359 instead of ‘358 when submitting their drug patent information 
for publication in the Orange Book, then Caraco could bring a 
counterclaim and require Novo to “correct” its incorrect listing.158  
The Court seriously doubts that Congress enacted a counterclaim 
provision to correct a minor error159 such as the mislabeling of a 
patent number.160  
                                                 
154 Id. at 1683.  The Court argues that the description of possible remedies for 
an overbroad use code destroys “whatever remains of Novo’s argument.”  Id. at 
1684. 
155 Id. at 1678.  “According to the statute, a successful claimant may obtain an 
order requiring the brand to ‘correct or delete’ its patent information.”  Id.  See also 
21 U.S.C. § 355 (j)(5)(C)(ii)(I) (2012). 
156 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1684.  Usually a brand 
manufacturer will choose to delete a listing from the Orange Book entirely when it 
holds no relevant patent, and will correct the information located in the listing 
when the brand manufacturer has incorrectly described the patent’s scope.  Id.  
157 Id. at 1685. 
158 Id.  The Court does not take this argument very seriously and believes that 
Novo “considerably understates the matter.”  Id.  
159 Id.  Novo conceded to the Court that brand companies have strong 
incentives to ensure that correct and accurate information is published in the 
Orange Book (they also have major incentives to immediately correct any false or 
incorrect information as soon as possible) because this information alerts both the 
FDA and other companies that their drug patent is valid.  Id.  In other words, 
publishing correct information in the Orange Book protects brand name 
manufacturers from infringement by generic brand manufacturers.  Furthermore, 
the Court believes that generic manufacturers would have absolutely no incentive 
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Furthermore, Novo has not even formulated a situation where the 
counterclaim provision would be used to correct inaccurate patent 
dates.161  Under Novo’s interpretation of the counterclaim, its use is 
only appropriate if a listed patent “does not claim the drug or an 
approved method of using it.”162  On the one hand, if a brand 
manufacturer mistakenly lists the expiration date of an otherwise 
valid patent (meaning it claims the drug or an approved use) as 2020 
instead of 2015, the generic manufacturer would be barred from 
bringing the counterclaim altogether (under Novo’s interpretation).163  
On the other hand, if the brand manufacturer mistakenly published a 
2015 expiration date when in reality the patent has already expired, 
then the generic company could make use of the counterclaim 
provision.164  However, in the latter situation, the correct remedy 
would be a delisting of the patent instead of a correction of the 
brand’s listing.165  Clearly, the counterclaim was created in order to 
correct and delist inaccurate use codes, and not only numbers and 
expiration dates under subsection (b) and (c) of 21 U.S.C. § 355.166 
 
                                                 
to bring a counterclaim against a brand name manufacturer merely to correct a 
mislabeled patent.  Id.  
160 Id.  See, e.g., TRW Inc. v. Andrews, 534 U.S. 19, 31 (2001) (refusing to 
adopt an interpretation of a statute that would render a piece of it “insignificant, if 
not wholly superfluous”).  If Novo’s interpretation of how the counterclaim 
provision works were true, the counterclaim would be almost entirely pointless.  
The Court points out that it would have been, “in the most literal sense, to make a 
federal case out of nothing.”  Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 
1685. 
161 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1685. 
162 Id. 
163 Id.  In the above hypothetical, “the counterclaim would be useless: It 
authorizes a remedy only ‘on the ground that’ the listed patent does not claim the 
drug or an approved method of using it—and notwithstanding the wrong expiration 
date, this patent does so.”  Id. 
164 Id. 
165 Essentially, “Novo's reading of ‘patent information,’ like its reading of ‘not 
an,’ effectively deletes the term ‘correct’ from the statute.”  Id. 
166 Id. 
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4. No Evidence Points to Congress Rejecting S. 812 Because It 
Required Brands to Submit Patent Information Beyond a 
Number and Expiration Date. 
Novo argues that the Court’s interpretation of 21 U.S.C. § 355 
basically revives parts of the Greater Access to Affordable 
Pharmaceuticals Act of 2002, which was expressly rejected by the 
United States Congress.167  The bill would have required brand name 
companies to file specific information for method-of-use patents, 
such as a description of “the approved use covered by the patent 
claim.”168  Moreover, S. 812 would have provided generic brand 
companies with their own form of civil action to compel brand name 
companies to “delete” or “correct” inaccurate information filed with 
the FDA.169  Novo argues that S. 812 would have allowed generic 
brand companies to challenge overbroad patent descriptions, and thus 
the Court “cannot read the statute Congress eventually enacted as 
doing so.”170  The Court wholeheartedly disagrees with Novo’s 
argument and sees no reason to assume that the reason Congress did 
not pass S. 812 was because it required brand name companies to 
submit a description of the approved uses claimed by the patent.171   
S. 812 had several titles and provisions, any of which could have 
been viewed unfavorably by Congress and been the reason for why 
the House of Representatives took no action on the bill.172  S. 812 
                                                 
167 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1685.  S. 812 was able to 
successfully pass through the United States Senate, however the House of 
Representatives never voted on the bill, thus preventing it from being enacted into 
Law.  Id. at 1686.  




171 Id.  The Court believes, just like any layperson would, that “a bill can be 
proposed for any number of reasons, and it can be rejected for just as many others.”  
Id. at 1686 (citing Solid Waste Agency of N. Cook Cnty. v. Army Corps of Eng’rs, 
531 U.S. 159, 170 (2001)).  Novo attempts to argue that S. 812 was rejected by 
Congress for one specific reason, however there were several aspects of S. 812 that 
were unappealing and thus altered.   
172 See generally S. 812, 107th Cong. § 804(b) (2002).  One of the biggest 
issues in S. 812 was Title II § 804 (b), which said, “[t]he Commissioner of 
Customs, shall promulgate regulations permitting pharmacists and wholesalers to 
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also received public criticism from several politicians because it 
called for an independent cause of action, which was a more lengthy 
legal action than the counterclaim provision that Congress ultimately 
adopted.173  Moreover, Novo completely ignored a major reason as to 
why the bill was redrafted.174  In between the demise of S. 812 and 
the counterclaim’s enactment, “the FDA issued a rule requiring 
brands to supply material concerning method-of-use patents, 
including use codes.”175  According to the Court, the drafters of the 
counterclaim provision were completely aware of the FDA ruling and 
did not want to “duplicate its list of mandated filings.”176  Ergo, the 
drafting history of the counterclaim does not support Novo’s ultimate 
conclusion of Congress rejecting S. 812 because it required brands to 
submit patent information beyond a patent number and expiration 
date.177 
 
5. Congress Did Not Establish the Counterclaim Merely to 
Solve the Problem Raised by the Federal Circuit’s Decision in 
Mylan. 
Novo made one last attempt at an argument and stated that 
“Congress established the counterclaim only to solve the problem 
raised by the Federal Circuit’s decision in Mylan— the impossibility 
of deleting an improperly listed patent from the Orange Book.”178  As 
discussed earlier, Mylan involved a situation where a generic drug 
                                                 
import prescription drugs from Canada into the United States.”  S. 812, 107th 
Cong. § 804(b) (2002).  Title II was highly controversial and likely would have 
resulted in numerous lawsuits between U.S. and Canadian pharmaceutical 
companies.  Id. 
173 E.g. Senator Gregg in discussing the challenges of passing S. 812 stated, 
“the most significant issue is the fact that [S. 812] creates a new cause of action.”  
148 CONG. REC. 15424 (2002) (remarks of Sen. Gregg).  Basically, “the creation of 
an independent cause of action [was] stronger medicine than the counterclaim 
Congress ultimately adopted.”  Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 
1686. 
174 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1686. 
175 Id. 
176 Id. 
177 Id.  The Court believes that “if anything, the statute's evolution indicates 
that Congress determined to enforce the FDA's new listing provisions, including its 
use–code requirement, through the new counterclaim.”  Id. 
178 Id. 
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manufacturer alleged that a brand name drug manufacturer submitted 
a patent that neither claimed the drug, or any of its approved uses; 
Mylan requested the patent be delisted.179  However, the court in 
Mylan found that delisting the patent was not a remedy available to 
Mylan180 under then current patent laws or the “Hatch–Waxman 
Amendments to the Federal Food, Drug, and Cosmetic Act (FFDCA) 
and to Title 35 of the United States Code.”181  Novo wanted the Court 
to strictly construe the counterclaim provision to only help generic 
drug manufacturers in Mylan’s exact situation.182  The Court once 
again disagrees with Novo.183 
Instead, the Court believes the decision in Mylan alerted 
Congress to a major problem, which was that “generic companies 
generally had no avenue to challenge the accuracy of brands’ patent 
listings, and that the FDA therefore could not approve proper 
applications to bring inexpensive drugs to market.”184  The Court 
finds proof of this in the statute and its context, which demonstrate 
that the counterclaim provision is available to generic companies 
when brand companies publish patents with no basis, as well as 
overbroad patents.185  Moreover, whether a brand name 
                                                 
179 See generally Mylan Pharm., Inc., v. Thompson, 268 F.3d 1323 (Fed. Cir. 
2001).  
180 “The Federal Circuit held that no such action was available, even assuming 
the allegation was true.  Because several legislators saw Mylan as ‘exemplifying 
brands' ‘perceived abuse’ of the FDA's patent listing practices.”  Caraco Pharm. 
Laboratories, Ltd., 132 S. Ct. at 1686–87. 
181 Mylan Pharm., Inc., 268 F.3d at 1325.  See also supra note 58. 
182 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1687. 
183 The Court does not draw any conclusions on whether the Mylan decision 
incentivized legislators to create a counterclaim or not.  Id.  Instead they 
emphasized the publishing of a study conducted by the FTC that deeply criticized 
brand name pharmaceutical companies, and illustrated how brand manufacturers 
would submit overbroad patents for publication to the FDA, thus preventing 
generic drug companies from bringing their version of the drug to market.  Id. 
184 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1687.  The Court lamented 
how “the statute's text and context demonstrate that the counterclaim is available 
not only (as in Mylan) when the patent listing is baseless, but also (as here) when it 
is overbroad.”  Id.  The opinion also goes on to say how “Congress's decision to 
allow a counterclaimant to seek ‘correction’ of patent information explodes Novo's 
theory, because the remedy for a Mylan–type impropriety is complete delisting.”  
Id. 
185 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1687. 
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pharmaceutical company publishes an overbroad patent or whether it 
publishes a patent that covers absolutely no approved use, the bottom 
line is that the company is “submit[ing] misleading information to the 
FDA.”186  Essentially, the brand name manufacturer takes advantage 
of the fact that the FDA does not have the manpower or necessary 
qualified individuals to police incorrect and misleading 
pharmaceutical drug patents.187  This prevents or severely delays 
generic drugs that should otherwise go to market.  Caraco’s situation 
was extremely serious, as Novo wanted to prevent Caraco from 
selling repaglinide for unpatented uses until 2018.188   
The Court considers Caraco to be in even more need of the 
counterclaim provision than Mylan, for several reasons.  In Mylan, 
the brand company listed a patent that claimed no approved use of 
the drug.189  When a brand company does this, the generic company 
has an alternative to the counterclaim provision, which is to make a 
paragraph IV certification maintaining that the published patent “is 
invalid or will not be infringed [on] by the generic drug.”190  If the 
brand manufacturer decides to sue the generic company, the generic 
company can argue that their drug will not infringe the patent.191  The 
use of the counterclaim by the generic manufacturer against the brand 
manufacturer may result in a quicker delisting of the patent, however, 
“even without it the [generic manufacturer] can eventually get a 
judgment of non-infringement enabling the FDA to approve its 
ANDA.”192  In Caraco’s situation, where a brand company 
purposefully files an overbroad use code description with the FDA, 
the generic manufacturer is unable to use a paragraph IV certification 
because it would require the generic manufacturer to propose 
labeling identical to the brand name drug; furthermore, it cannot 
                                                 
186 Id. 
187 Id.  When brand name pharmaceutical companies submit incorrect patent 
information, their actions “delay or block approval of a generic drug that infringes 
no patent – and that under the statute should go to market.”  Id.  This is “the danger 
Caraco faces here, as much as it was the threat in Mylan: Novo seeks to preclude 
Caraco from selling repaglinide for unpatented uses until 2018, when Novo's patent 
on a different use expires.”  Id. 
188 Id.  
189 Mylan Pharm., Inc. v. Thompson, 268 F.3d 1323 (Fed. Cir. 2001). 
190 See 21 U.S.C. § 355(j)(2)(A)(vii)(IV) (2012). 
191 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1687. 
192 Id.  
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carve out any uses.193  The proposed label will “infringe because it 
will include the use(s) on which the brand does have a patent.”194  
Thus, in Caraco’s situation, “a paragraph IV suit cannot lead to a 
judgment enabling FDA approval.”195  The counterclaim provides the 
only way for Caraco (or a generic drug manufacturer in a similar 
situation) to bring its drug to market for “non-infringing uses.”196  
Novo’s view would eliminate the counterclaim, thus preventing it 
from being used where it is most helpful to generic drug 
manufacturers.197  Thus, the Supreme Court in a 9-0 opinion ruled in 
favor of Caraco. 
 
B.  Justice Sotomayor’s Concurring Opinion 
Justice Sotomayor concurs with the Court’s interpretation of the 
counterclaim in section 355198 and agrees that its reading of the 
statute is the most sensible “in light of the existing regulatory 
scheme.”199  However, she writes separately to make several 
additional observations.200  
Sotomayor strongly believes that the counterclaim in section 355 
can only “lessen the difficulties created by an overly broad use code; 
it cannot fix them.”201  Section 355 was specifically designed to 
increase the production and approval time of generic drugs by the 
FDA, so that American citizens have the option of purchasing a more 
                                                 
193 Id.  “A paragraph IV certification (unlike a section viii statement) requires 
the generic company to propose labeling identical to the brand's; it cannot carve out 
any uses.”  Id.  See supra note 50.  
194 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1687. 
195 Id. 
196 Id. at 1687–88. 
197 Id. at 1688. 
198 Id.  See also 21 U.S.C. § 355(j)(5)(C)(ii)(I) (2012).  Justice Sotomayor 
agrees with the Court’s interpretation of the counterclaim in section 355 “to permit 
generic manufacturers to force brand manufacturers to ‘correct inaccurate use 
code.’”  Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1688 (Sotomayor, J., 
concurring).  She too finds “the counterclaim not ‘free of ambiguity.’”  Id. 
199 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1688  (Sotomayor, J., 
concurring). 
200 Id. (Sotomayor, J., concurring). 
201 Id. (Sotomayor, J., concurring). 
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affordable version of their pharmaceutical drug.202  The generic drug 
manufacturer must submit an ANDA with a section viii statement to 
the FDA.203  Once the FDA receives the ANDA and section viii 
statement, it can approve the application without further delay, as 
long as the use code is not overly broad.204  When an overly broad 
use code is submitted to the FDA, the process becomes much more 
complicated.205  Sotomayor correctly points out that the Court’s 
decision now permits generic drug manufacturers to bring a 
counterclaim against the brand name manufacturer, once the brand 
name manufacturer sues the generic company for patent 
infringement.206  If the generic company successfully litigates the 
                                                 
202  “The statutory scheme is designed to speed the introduction of low–cost 
generic drugs to market.”  Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1688 
(Sotomayor, J., concurring) (citing Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 
661, 676 (1990)). 
203 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1688 (Sotomayor, J., 
concurring).  Along with the ANDA and section viii statement, the generic drug 
company must submit a “proposed label that ‘carves out’ from the brand 
manufacturer’s label any patented method of use.”  Id.  See supra note 50 
(providing an explanation of “carving out”). 
204 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1688 (Sotomayor, J., 
concurring). 
205 Id. (Sotomayor, J., concurring).  The reason an overbroad use code 
complicates things is very straightforward.  The Federal Drug Administration 
“relies on use codes in determining whether to approve an ANDA, but it refuses to 
evaluate the [use code’s accuracy].”  Id. (Sotomayor, J., concurring).  “If the use 
code overlaps with the generic manufacturer's proposed carve–out label (i.e., the 
use code is overly broad), FDA will not approve an ANDA with a section viii 
statement.”  Id. (Sotomayor, J., concurring). 
206 Id. at 1688 (Sotomayor, J., concurring).  
 
After today's opinion, the generic manufacturer can respond 
to this situation by taking the following steps: submit an ANDA 
with a paragraph IV certification (which requires a proposed 
label materially identical to the brand manufacturer's label), wait 
for the brand manufacturer to institute suit, file a counterclaim, 
and then litigate the counterclaim.  [If the generic company is] 
successful in securing the correction of the use code, [it can] 
return to the start of the process and do what it always wanted to 
do—file an ANDA with a section viii statement and a carve–out 
label. 
 
Id. (Sotomayor, J., concurring). 
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counterclaim and compels the brand name company to either correct 
or delete the overbroad use code, they can return to the beginning of 
the process and submit their ANDA, section viii statement, and 
carve-out label.207  
Justice Sotomayor finds two major problems with the 
counterclaim provision.  First, it results in major delays and 
expenses, which the statutory scheme did not foresee; second, there is 
absolutely no guarantee that the process will work.208  The Court 
knows what will happen if a brand company initiates paragraph IV 
litigation over an overbroad use code,209 but it is unclear “if the brand 
name company does not file.”210  Justice Sotomayor strongly believes 
the counterclaim “cannot restore the smooth working of a statutory 
scheme thrown off kilter by an overly broad use code.”211  At the 
very best, the statutory scheme allows the generic drug manufacturer 
to file an ANDA with a section viii statement, “but only after 
expensive and time-consuming litigation.”212  Justice Sotomayor 
laments that either the FDA or Congress needs to take action and 
address the problem.213 
                                                 
207 Id. (Sotomayor, J., concurring). 
208 Id. at 1688–89 (Sotomayor, J., concurring). 
209 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1689 (Sotomayor, J., 
concurring).  The outcome of paragraph IV litigation over an overbroad use code 
“will be the correction of the use code through the assertion of a counterclaim—an 
outcome that is desirable, to be sure, for the generic manufacturer, but perhaps less 
so for the brand manufacturer.”  Id. at 1689 (Sotomayor, J., concurring). 
210 Id.  The FDA “may approve the generic manufacturer's application, 
‘without prejudice to infringement claims the patent owner might assert when the 
ANDA applicant produces or markets the generic drug.’”  Id. (Sotomayor, J., 
concurring).  However, the generic brand manufacturer having been forced to 
continue with a paragraph IV certification, “will have secured approval to market a 
drug with a label materially identical to the brand manufacturer's.”  Id. (Sotomayor, 
J., concurring).  The Solicitor General's Office informed the Court at oral 
arguments that “it would be inducement of infringement to sell a product with 
labeling that suggests that the product be used for a patented method of use.”  Id. 
(Sotomayor, J., concurring).  Basically, if a generic drug manufacturer filed a 
paragraph IV certification, the proposed labeling would be infringing, so long as 
the brand name manufacturer’s patent covered an approved method of using the 
approved drug.  Id. (Sotomayor, J., concurring). 
211 Id. (Sotomayor, J., concurring). 
212 Id. (Sotomayor, J., concurring). 
213 Id. (Sotomayor, J., concurring). 
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Sotomayor goes on to say that the regulatory scheme is dependent 
on the accuracy of the use codes, and that the FDA’s “guidance as to 
what is required of brand manufacturers in use codes [is] remarkably 
opaque.”214  Some of the confusion is due to the FDA’s failure to 
describe what is required of brand name manufacturers; Novo 
experienced difficulties and confusion in filing their use code 
description with FDA.215  However, the Court explained in its 
                                                 
214 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1689 (Sotomayor, J., 
concurring).  “The relevant regulation states simply that a brand manufacturer must 
provide ‘[t]he description of the patented method of use as required for 
publication.’”  Id. (Sotomayor, J., concurring) (citing 21 C.F.R. § 
314.53(c)(2)(ii)(P)(3)).  The new drug application forms contain information with 
additional details explaining how: 
 
Each approved use claimed by the patent should be separately 
identified . . . and contain adequate information to assist . . . 
applicants in determining whether a listed method of use patent 
claims a use for which the . . . applicant is not seeking approval.  
 
Id. at 1689 (Sotomayor, J., concurring).   
However, the form also mentions that brand name drug companies may “use no 
more than 240 total characters including spaces.”  Id. (Sotomayor, J., concurring).  
Elsewhere, the “FDA acknowledges ‘that in some cases 240 characters may not 
fully describe the use as claimed in the patent.’”  Id. (Sotomayor, J., concurring) 
(citing 68 Fed. Reg. 36683 (2003)).  This indicates that use codes “are not meant to 
substitute for the applicant's review of the patent.”  Caraco Pharm. Laboratories, 
Ltd., 132 S. Ct. at 1689 (Sotomayor, J., concurring). 
215 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1689 (Sotomayor, J., 
concurring).  Sotomayor points out that when Novo filed its initial NDA, it 
“submitted a use code for the § 358 patent that was not ‘overly broad’: It described 
narrowly the single patented method of use.”  Id. (Sotomayor, J., concurring).  
Several years later the FDA required Novo to amend its label to “separate all 
indications with the following sentence: ‘Prandin is indicated as an adjunct to diet 
and exercise to improve glycemic control in adults with type [two] diabetes 
mellitus.’”  Id. at 1690 (Sotomayor, J., concurring).  Novo proceeded to amend its 
use code to comply with the FDA requirements, and explained that the amendment 
corresponded with the requests of the FDA.  Novo believed its newly amended use 
code “[complied] with FDA regulations, . . . on the ground it pressed before [the 
Court]: that the regulations permit a brand manufacturer to submit for publication 
in the Orange Book a description of either the patented method of use or the 
indication (which refers to ‘what a drug does’).”  Id. at 1690 (Sotomayor, J., 
concurring). 
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majority opinion why Novo was mistaken, yet Sotomayor believes 
“[Novo] can hardly be faulted for so thinking.”216 
Justice Sotomayor concludes by mentioning that prior to the 
enactment of the counterclaim provision, “Congress considered a bill 
that required brand manufacturers to submit a description of the 
approved use covered by the patent claim.”217  The legislation 
allowed a generic manufacturer to bring an independent civil action 
and force a brand name manufacturer to correct or remove an 
overbroad use code.218  S. 812 received all kinds of criticism and was 
eventually rejected by Congress.  Politicians stated that the bill would 
encourage excessive litigation.219  Sotomayor believes “[a]bsent 
greater clarity from FDA concerning what is required of brand 
manufacturers in use codes, Congress’s fears of undue litigation may 
be realized.”220 
 
VI.   POSSIBLE SOLUTIONS 
Justice Sotomayor’s concurring opinion indicates that the Court’s 
decision in Caraco has not even come close to fixing all of the 
problems associated with the counterclaim provision and that both 
Congress and the FDA must take further steps to achieve a complete 
resolution.221  As it stands today, the FDA will not review the patents 
submitted to it for compliance with the Hatch-Waxman Amendments 
                                                 
216 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1690 (Sotomayor, J., 
concurring).  “The regulations also require submission of “a description of each 
approved method of use or indication.”  Id. (citing 21 C.F.R. § 
314.53(c)(2)(ii)(P)(1)).  Also, the form on which the brand name drug company 
submits its use code “requires information on the indication or method of use for 
the Orange Book ‘Use Code’ description.”  Id. (Sotomayor, J., concurring).  
Sotomayor states that “those sources at the least suggest (as Novo thought) that a 
method of use here is distinct from an indication and that either suffices as a use 
code.”  Id. (Sotomayor, J., concurring).  
217 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1690 (Sotomayor, J., 
concurring).  
218 Id. (Sotomayor, J., concurring). 
219 Id. (Sotomayor, J., concurring).  See supra notes 171–173.  
220 Caraco Pharm. Laboratories, Ltd., 132 S. Ct. at 1690 (Sotomayor, J., 
concurring). 
221 Id. 
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that were passed in 1984.222  The agency adopts a “hands-off” policy 
when it comes to patents and refuses to conduct any type of due 
diligence to safeguard from overly broad or inaccurate method-of use 
codes being submitted for publication in the Orange Book.223  The 
FDA’s current hands-off position is the reason why certiorari was 
granted for the Caraco case, because the FDA’s “policy incentivizes 
[brand manufacturers] to draft use code narratives that are 
inappropriately broad to force applicants to file Paragraph IV 
certifications.”224 
 
A. Increase the Level of Review 
Prior to the Court’s decision in Caraco, two senior attorneys (Mr. 
Malkin and Mr. Wasson) published an article making several 
recommendations for how the FDA should proceed.  Their 
suggestions were criticized, yet they are now more relevant than 
ever.225  In essence, they suggest that the FDA “internally review 
patents beyond the ministerial requirements of its current regulations 
to more efficiently administer the balance between an NDA-holder 
and generic applicant.”226  First, and most importantly, the FDA 
should review patents submitted for publication in the Orange Book 
for accuracy and “should proactively refuse to list patents that do not 
meet FDA’s listing criteria.”227  Second, “in the event that an 
applicant submits carved-out labeling, confirm that the listed method-
of-use patent does not claim a use for which the application is 
                                                 
222 The FDA has stated: “because FDA has no expertise in the field of patents, 
the agency has no basis for determining whether a use patent covers the use sought 
by the generic applicant.”  Abbreviated New Drug Application Regulations; 
Proposed Rule, 54 Fed. Reg. 28872, 28909 (July 10, 1989).  See also supra note 
52, where the FDA explains how its administration lacks both the expertise and 
authority to review patent claims. 
223 Id. 
224 Brian J. Malkin & Andrew S. Wasson, Should FDA Undertake More Than 
A Ministerial Role With Respect to Patent Information?, 1 THE FOOD AND DRUG 
LAW INST. FOOD AND DRUG POL’Y FORUM 1, 1 (2011) [hereinafter FDA: 
Ministerial Role]. 
225 See generally Malkin & Wasson, supra note 224.   
226 Id. at 5.  Malkin and Wasson advocate for various limits on the internal 
review.  Id.  
227 Id. 
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submitted.”228  The FDA should be allowed to retain use code 
narratives for informational use, so that they might refer back to them 
or compare them to future submissions.229 
A major benefit of the above proposal is that the FDA will be 
able to act as a “neutral arbiter” and hold NDA applicants 
accountable for inaccurate information they submit for publication in 
the Orange Book.230  The FDA would be able to unilaterally delist 
patents that have over broad use codes.231  Giving the FDA the ability 
to delist patents takes this power out of the hands of brand 
manufacturers (who often times have an interest in publishing 
overbroad use codes) and places it in the hands of a “neutral 
arbiter.”232  Brand name manufacturers would have an incentive not 
to submit overbroad or inaccurate method-of-use patents for fear that 
they would be rejected by the FDA.  Malkin and Wasson point out 
how this exact reasoning applies to the “FDA’s role in determining 
whether an applicant can carve-out . . . a product.”233  Basically, 
instead of the brand manufacturer having the sole power to decide the 
scope of the patent, which could potentially prevent a non-infringing 
generic drug manufacturer from achieving the approval of their 
“505(b)(2) ANDA, the FDA would ‘assume the decision making 
role.’”234  Most likely, “the number of questionable patent listings 
and use code narratives would decrease . . . because [brand 
manufacturers] would be less likely to submit inappropriate patent 
listings or use codes’ narratives knowing that this information would 
face a substantive FDA review.”235  Brand name manufacturers 
would be dissuaded from submitting inaccurate use codes to the FDA 
for publishing if there was a possibility that the patent could be 
rejected because its method-of-use statement is overbroad or wholly 
inaccurate. 
                                                 
228 Id.  
229 Id. 
230 FDA: Ministerial Role, supra note 224, at 6. 
231 Id. 
232 Id.  Placing this type of power in the hands of the FDA would provide some 
“balance between competing interests.”  Id. 
233 Id. 
234 Id.  
235 FDA: Ministerial Role, supra note 224, at 6.  
 Journal of the National Association of Administrative Law Judiciary 33-1 380 
 
B. Hire Patent Attorneys With Backgrounds in 
Pharmaceuticals or Medicine 
The FDA has made it completely clear that it does not “have the 
expertise to review patent information,” which is why the FDA needs 
to hire patent attorneys with a background in pharmaceuticals or 
medicine.236  Having a small staff of patent attorneys with medical or 
scientific backgrounds “would confer other benefits on FDA.”237  
The attorneys could assist with legal interpretations of “other 
complicated scientific issues that have regulatory and legal 
implications, such as the . . . biosimilars legislation or difficult 
scientific/regulatory issues like some bioequivalence 
determinations.”238  Furthermore, FDA patent attorneys could “work 
with the Patent Office on the patent term restoration program, which 
was also included in the Hatch-Waxman Act, allowing the FDA to 
engage in more robust and efficient discussions with the Patent 
Office on eligibility and regulatory review period determinations.”239  
Having attorneys on staff who are experienced in patent law and have 
a thorough understanding of the scientific and medical realms would 
allow the FDA to react more quickly to unexpected and complicated 
patent issues that arise.240 
The FDA’s legal department could begin small with four or five 
patent attorneys and make adjustments in the future as needed.  The 
median salary for an attorney employed by the United States 
Government is $87,008.241  Assuming the FDA is able to employ six 
patent attorneys and pay each of them a median salary, they would 
                                                 
236 Id.  Malkin and Wasson “concede that the analysis of determining whether 
a method–of–use patent claims a use for which the generic application is submitted 
requires a more refined skill–set than a patent listing determination . . . this analysis 
would not be beyond the skills of the competent patent attorneys hired by the 
FDA.”  Id.  
237 Id. at 7.  
238 Id.   
239 Id. 
240 FDA: Ministerial Role, supra note 224, at 7.  
241 See Pay Scale: Attorney, Government Salary (Feb. 6, 2013), available at 
http://www.payscale.com/research/US/Job=Attorney,_Government/Salary.  
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need to come up with an additional $522,048 per year ($43,504 per 
month) in order to fund the legal department.242 
 
VII. FDA COUNTERARGUMENTS 
The FDA might make several counterarguments against adopting 
the above suggestions; however, senior attorneys Malkin and 
Wasson, as well as Justice Sotomayor, provide several compelling 
counterarguments to the FDA taking a “hands-off” approach. 
 
A. The Scope and Validity of Patents Belong With the Courts 
The FDA has argued that expanding its role will be extensive and 
that it will not be able to accomplish the task due to its lack of 
experience.243  However, Malkin and Wasson highlight how the FDA 
has some experience in determining difficult and complex issues, 
“for example, responding to FTC’s call to clarify types of patents 
appropriately listed in the Orange Book.”244  The FDA is already 
familiar with the “hallmarks and characteristics” of various 
pharmaceutical patents, and it is not unreasonable to ask the FDA to 
perform a more thorough job in determining whether a patent that has 
been submitted for publication meets the FDA’s criteria.245  The FDA 
has mentioned that it would rather focus on ensuring that drugs are 
safe and effective for the American public and let drug manufacturers 
sort out their differences that arise from paragraph IV.246  However, 
if the FDA would take a more hands on approach and review NDA 
applications for accuracy, it may very well cut down on litigation and 
solve part of the problem.  
Furthermore, the FDA’s previous contention that “disputes 
relating to the scope and validity of patents . . . belong with the 
                                                 
242 Id. 
243 FDA: Ministerial Role, supra note 224, at 7. 
244 Id.  In this particular situation the “FDA made a fine–grained determination 
that patents claiming active ingredients, formulations, methods of use, products–
by–process and polymorphs could be listed in the Orange Book, while patents 
claiming metabolites, packaging, intermediates and processing could not be listed 
in the Orange Book.”  Id. 
245 Id. 
246 Id.  
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courts, given the court’s experience, expertise and authority in 
complex patent matters,” may be dead in the water, given Justice 
Sotomayor’s concurring opinion urging Congress and the FDA to 
take further action.247  Prior to the Supreme Court’s decision in 
Caraco, the District Courts and the Federal Circuits, “ratified FDA’s 
position,” that they “lack expertise to weigh in on patent issues.”248  
However, in Caraco, Sotomayor specifically criticizes the FDA’s 
guidance, referring to it as “remarkably opaque;” she also mentions 
how the FDA’s approach towards reviewing use codes was part of 
the reason why Caraco went all the way up to the Supreme Court.249  
Hopefully the FDA will recognize the Supreme Court’s criticisms 
and take to heart what the Court and Malkin and Wasson have 
suggested. 
 
B. The FDA’s Patent Decisions Would Lead to 
Increased Litigation Against the Agency 
Finally, the FDA may attempt to argue, “FDA’s patent decisions 
would inevitably lead to increased litigation against the agency.”250  
Malkin and Wasson highlight that while this may be true in the short 
run, “avoiding litigation should not be a guiding principle for sound 
regulatory policy.”251  Simply put, the FDA cannot refrain from 
making substantive decisions just because one of the decisions could 
potentially end up in litigation.252  Not to mention, if the FDA hires 
several patent attorneys, they would be able to effectively handle any 
lawsuit brought against the agency.  The FDA might also argue that 
“there is no guarantee that a more robust patent review procedure 
                                                 
247 Id. 
248 FDA: Ministerial Role, supra note 224, at 7.  “[I]t is . . . true that these 
courts have found FDA’s position to be reasonable, . . . these courts do not appear 
to mandate that the FDA maintain this policy, especially in light of the 
circumstances where it is not working or it causes a delay in the availability of 
generic products.”  Id. 
249 See supra notes 209–10. 
250 FDA: Ministerial Role, supra note 224, at 7. 
251 Id.  The FDA is in the “business of making substantive decisions: each 
could potentially end up in litigation.”  Id.  The FDA “would be paralyzed if it did 
not act due to fear of litigation.”  Id. 
252 Id. 
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would lead to facilitated generic entry.”253  However, it appears that a 
more substantive and robust review procedure would have 
“facilitated generic entry” in the case of Caraco.254  If a more 
proactive FDA would have made the decision that the “listed 
method-of-use patent did not claim a use for which the generic 
applicant submitted the application, the generic applicant would have 
been allowed to maintain its statement under subsection viii and 
would not have been subject to . . . unnecessary litigation.”255 
 
VIII.   RECENT FDA AND CONGRESSIONAL DEVELOPMENTS 
In the past, the FDA has criticized the idea of taking a “more 
hands on approach” when it comes to increasing its substantive level 
of review of drug patents.  Currently, “A Generic Drug User Fee Act 
is on the way, to enable the U.S. Food and Drug Administration to 
levy a user fee of around $100,000 on each generic drug application 
filed for approval.”256  As of now, there is no fee for filing an ANDA 
with the FDA.257  According to estimates made by Infrastructure 
Development Finance Corporation (IDFC Securities),258 once 
Congress passes the act, it will generate an “additional $229 million 
per annum from generic [drug manufacturers].”259  Of the $229 
million, “30% is likely to come from the processing of ANDA’s and 
drug master files [license to make bulk drugs], and the rest from its 
inspection of various facilities.”260  Other sources have mentioned 
                                                 
253 Id. 
254 Id.  
255 FDA: Ministerial Role, supra note 224, at 7. 
256 U.S. to Charge Fee on Generic Drug Sale Application, BUSINESS 
STANDARD (June 21, 2012), available at http://www.business-
standard.com/article/companies/us-to-charge-fee-on-generic-drug-sale-application-
112062100065_1.html [hereinafter Fee’s on Generic Drug Sale Applications]. 
257 Id. 
258 IDFC Securities limited is a subsidiary of Infrastructure Development 
Finance Corporation and “provides corporate finance and institutional securities 
services.”  Company Overview of IDFC Securities Limited, BLOOMBERG 
BUSINESSWEEK (May 26, 2013), available at 
http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=
35248900. 
259 Fee’s on Generic Drug Sale Applications, supra note 256. 
260 Id. 
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that these estimates could vary, depending on “the product’s market 
size.”261  The proposed legislation is “expected to give the FDA the 
additional resources required to improve the review of drug 
[patents].”262  The additional revenue raised from the passage of this 
act should give the FDA breathing room to hire additional patent 
attorneys who will thoroughly review and analyze complex patent 
issues and situations.  Furthermore, the FDA’s legal department will 
be able to handle any lawsuit filed against the agency that relates to 
the FDA’s patent decisions.  The additional revenue should also 
make the FDA’s patent review process more effective, as the agency 
will be able to hire additional members that will be tasked with 
reviewing drug applications to make sure they comply with the 
statutory requirements.  
The recent development of a “Generic Drug User Fee Act” is 
extremely significant, and it is in everyone’s interest to get the 
legislation passed as soon as possible, as a “significant number of 
Indian companies are targeting various generic launches in the U.S., 
in the wake of expiring patents.”263  Indian drug companies play a 
major role in the U.S. market, and make up around ten percent of the 
U.S. pharmaceutical market.264  It is extremely important for 
Congress to quickly pass the Generic Drug User Fee Act, so that the 
FDA does not miss out on the potential for major increases in its 
revenue from the filing of ANDA applications on behalf of Indian 
pharmaceutical companies.265 
 
IX.  CONCLUSION 
The United States Supreme Court decision in Caraco was a 
landmark decision in the pharmaceutical industry, especially for 
generic drug manufacturers like Caraco.  The unanimous decision by 
the Court made it clear that generic manufacturers may bring a 
                                                 
261 Id. 
262 Id.  “Currently, it takes the regulator an average of 30 months to review an 
application; it aims to reduce the review time to 10 months by 2017.”  Id. 
263 Id.  “Sales by Indian companies make up around 10 percent of the U.S. 
market.”  Id.  Indian drug companies file around 1,000 generic applications in the 
U.S. market every year.  Id. 
264 Fee’s on Generic Drug Sale Applications, supra note 256. 
265 Id. 
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counterclaim to compel brand name manufacturers to either correct 
or delete overbroad method-of-use codes.  The Court’s ruling closed 
a longstanding loophole that has been exploited by brand name 
manufacturers since the late 1990’s.  However, Justice Sotomayor 
made it readily apparent that the Court’s decision neither addressed 
all questions nor fixed all the problems with the counterclaim 
provision.  The FDA to this day takes a “hands-off” approach when it 
comes to the substantive review of method-of-use codes submitted by 
brand name drug manufacturers for publication in the Orange Book.  
In order to solve many of the lingering issues, the FDA must rise 
to the occasion and raise its substantive level of review, police patent 
codes for accuracy, and proactively refuse to list overbroad method-
of-use patents that do not comply with FDA requirements.  
Furthermore, the FDA should create a separate legal department and 
hire several patent attorneys with backgrounds in science to grapple 
with the more complicated patent issues that arise.  The FDA can no 
longer argue that U.S. courts support its “hands-off” level of review 
approach, as Sotomayor criticizes their current approach and urges 
the FDA to make major changes.  After the Caraco decision, it 
appears that both the FDA and Congress are working together to 
provide for major changes regarding the FDA’s review of drug 
patents.  Congress will likely pass a “Generic Drug User Fee Act,” 
which will allow the FDA to charge generic manufacturers up to 
$100,000 per ANDA application.  It is estimated that the new act will 
generate upwards of $200 million dollars per year in revenue for the 
FDA, which should cover its costs for patent attorneys, and greatly 
increase the ANDA approval rate.  It seems that both Congress and 
the FDA have heard the cries from the Supreme Court, especially 
those of Justice Sotomayor, and are working to develop a solution as 
quickly as possible. 
